H. Coelingh Bennink
Pantarhei Bioscience
Pantarhei Bioscience

HRA Pharma Acquires a Novel Ovarian Cancer Immunotherapy from Pantarhei Bioscience

Paris, FRANCE and Zeist, NETHERLANDS October 27, 2014 - HRA Pharma and Pantarhei Bioscience announced today that HRA Pharma has acquired exclusive global rights to develop and commercialize a novel ovarian cancer immunotherapy. Based on immunization against zona pellucida protein ZP3, the new therapeutic approach targets the prevention and treatment of certain types of ovarian cancer.


Read morepdf file

printer friendly version of this page   refer this page to a colleague
Copyright © Pantarhei Bioscience 2014| Disclaimer